Articles tagged with Drug Targets
Researchers have discovered a family of genes essential for tuberculosis survival during airborne transmission, providing new drug targets. The study sheds light on the bacterium's protective mechanisms, which could prevent infection spread and treat existing cases.
Researchers at Vanderbilt University Medical Center aim to use artificial intelligence technologies to generate antibody therapies against specific antigen targets. The project, funded by $30 million from ARPA-H, will create a massive antibody-antigen atlas and develop AI-based algorithms to engineer antigen-specific antibodies.
Magnetic nanoparticles are guided to tumors using a magnet and heated by a laser to destroy cancer cells. Researchers developed nanoparticles that outperform conventional photothermal agents, killing cancer cells with high efficiency.
A new study by researchers at UCSF has found that long-acting injectable treatments can be transformative for patients who struggle to take daily HIV pills, resulting in undetectable viral loads and improved health outcomes. The treatment approach could help stop the spread of HIV by keeping more patients from being infectious.
The Aligning Science Across Parkinson’s (ASAP) initiative offers funding of up to $6M for research community members to develop sustainable tools for Parkinson’s disease research. The funding supports the development of preclinical models, detection reagents, and modulation agents to accelerate therapeutic research.
The new AI model leverages hypergraphs to quickly and accurately identify therapeutic gene targets for diseases. HIT outperformed existing models in all tested metrics, demonstrating its accuracy in classifying therapeutic gene targets with great precision.
Core-shell nanoparticles offer effective drug encapsulation, shielding from degradation, and controlled release. This innovation enables targeted drug delivery, improving treatment outcomes and reducing side effects. The versatility of these nanoparticles allows for tailored materials to suit different therapeutic needs.
Researchers at VCU Massey Comprehensive Cancer Center have identified an innovative combination treatment strategy that collaborates to kill AML cells. The new approach targets the SRC gene and MCL-1 protein, leading to increased cell death in leukemia cells. This discovery offers a promising new direction for leukemia treatment.
Researchers explore ataciguat to manage aortic valve stenosis, showing potential to significantly slow disease progression. The drug may enable a once-in-a-lifetime procedure by delaying valve replacement surgery.
Researchers have discovered several novel downstream p53 targets that could lead to improved cancer therapies. The study highlights the critical role of p53 in preventing cancer and identifies two new genes, ALDH3A1 and NECTIN4, as potential targets for cancer treatment.
The FDA has approved a new treatment for Parkinson's disease that can adjust to the individual's brain activity, providing precise stimulation. This technology, known as adaptive deep brain stimulation (aDBS), detects patterns of brain activity and delivers tailored electric pulses to reduce symptoms.
The University of Texas at Arlington is joining forces with the Texas A&M Engineering Experiment Station to operate a new biomanufacturing center. This partnership will expand UTA's capabilities and provide access to financial support and industry partners, enabling researchers to develop and commercialize production of new bioprod...
Recent research suggests that select athletes with cardiovascular abnormalities can safely participate in competitive sports after shared decision-making with their clinicians. The new scientific statement reviews best clinical practices for athletes with certain cardiovascular conditions and provides an evidence-based path for safe re...
Cancer cells work together to source nutrients from their environment, a cooperative process that can be targeted for treating cancer. Researchers identified key enzymes and mechanisms behind this cooperation, including the enzyme CNDP2, which can be inhibited by the drug bestatin.
A new study published in the Journal of Antimicrobial Chemotherapy has found that lenacapavir is effective in controlling HIV in a population of patients in Uganda. The study sequenced the capsid proteins from 546 Ugandan patients and found little natural resistance to the drug.
Scientists at Nagoya University have developed a new mRNA technology that can produce up to 200 times more protein than traditional methods. This breakthrough enables the creation of healthy proteins to treat illnesses or toxic proteins to kill unwanted cells.
Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.
Researchers at Virginia Tech have developed a method to convert gut bacteria into mini protein factories that produce and release sustained flows of targeted proteins within the lower intestine. This approach eliminates a major roadblock in delivering drugs to this part of the body, offering potential treatment for chronic diseases.
Researchers at University of Gothenburg have identified a critical mechanism to slow down Crohn's disease progression by repairing the protective barrier of the gut. By reinforcing the gut's natural defenses, new drug targets may be developed to treat the disease.
The Colorectal Cancer Alliance has awarded new grants to researchers, convened top scientists at the Cure CRC Summit, and launched K-SPY, a groundbreaking multi-center platform trial for high-risk colorectal cancer cases. The initiative aims to improve outcomes for millions affected by the disease.
Researchers created optimized DNA hydrogels with fewer nucleic acids, achieving efficient and sustained drug release. The new hydrogel units showed prolonged persistence of at least 168 hours post-administration in mice, contributing to anti-tumor effects.
Researchers at Virginia Tech have developed a way to convert gut bacteria into miniature protein factories that produce and release targeted proteins inside the lower intestine. This breakthrough could potentially treat chronic diseases.
Researchers from the University of Gothenburg have made a breakthrough in understanding the role of protein tau in Alzheimer's disease. By identifying specific amino acid modifications that occur before thread-like fibrils form, scientists hope to develop complementary drugs to combat the disease.
A new study from the University of Pennsylvania School of Medicine has created a comprehensive genetic map of over 1,000 genes influencing kidney function, providing new insights into the causes of kidney disease. The researchers discovered that proximal tubule cells are a key
Researchers found that clot-dissolving medication alteplase improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke. This breakthrough may provide hope for stroke patients worldwide who may not have access to clot-dissolving medications within the approved time window.
A large genetic dataset and multi-omics approach identified 58 novel drug targets for both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). The study highlights the importance of developing targeted therapies for both subtypes, which have limited therapeutic options.
A new drug-free intervention targets the root cause of progressive loss of neural function in SMA by gradually reawakening functionally silent motor neurons. Early results show improved leg muscle strength and walking in adults with SMA, regardless of symptom severity.
Researchers at the University of Cincinnati presented studies on intracerebral hemorrhage treatment eligibility, finding only 3% of patients are eligible for a minimally invasive procedure. Additionally, a study found racial disparities in stroke recovery, with Black individuals experiencing worse functional outcomes after ischemic str...
The DISTAL trial found that endovascular therapy in addition to best medical therapy did not reduce disability more than clot-busting treatment alone for patients with medium distal vessel blockages. The study showed that mechanical clot removal was a safe option, but its benefits were uncertain.
Researchers at Tokyo University of Science have found that opioid delta-receptor agonists can alleviate stress-induced IBS symptoms in a validated mouse model by targeting the central nervous system. The study suggests that these drugs could provide a more definitive solution for IBS with minimal adverse effects.
Researchers discovered that a topical ABT-263 treatment effectively reduces aged skin senescence markers, priming the skin for improved subsequent wound healing. The treatment also triggered inflammation, which surprisingly helped the healing process by 'waking up' the skin's repair systems.
A recent study found that Streptococcus anginosis, a common mouth bacteria, is abundant in the guts of people with acute stroke and linked to a worse prognosis. The researchers also discovered that levels of this bacteria were associated with increased mortality rates two years after stroke.
A Texas A&M University researcher found that reducing alcohol consumption aligns with a harm reduction approach, which may be a more feasible approach for high-risk college drinkers. The study surveyed 822 high-risk college students and analyzed their intention to reduce drinking using the Theory of Planned Behavior.
A new algorithm proposes measuring quadriceps muscle mass for more accurate sarcopenia diagnosis, potentially leading to earlier detection and better treatment options. Ultrasound imaging is recommended as a cost-effective and practical solution for diagnosing sarcopenia in clinical settings.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
Researchers used AI to identify genetic factors in Parkinson's disease progression and FDA-approved drugs that can be repurposed for treatment. The study found potential risk genes like SNCA and LRRK2, which are known to cause inflammation, and identified candidate drugs such as simvastatin.
The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.
A study found that people with delayed REM sleep have higher levels of toxic proteins amyloid and tau, and lower levels of healthy protein BDNF, which can increase the risk of developing Alzheimer's. Practicing healthy sleep habits may help mitigate this risk.
A new microdosing approach using low doses of buprenorphine has been tested on patients with opioid use disorder, but most found it ineffective. The study, which included 126 participants, showed that only 34% were able to work up to a full dose of buprenorphine.
A recent study found that long COVID is more prevalent in women than men, and the association was linked to factors such as age, pregnancy, and menopausal status. The research highlights the need for targeted drug development and improved management strategies for long COVID.
BioChatter bridges the gap between large language models and biomedical research by providing a transparent and adaptable framework for custom research tasks. The platform can integrate with knowledge graphs and bioinformatics tools, making it easier for researchers to analyze complex datasets.
Biofilm produced by Pseudomonas alcaligenes has unique structural properties and thermal stability, exhibiting antioxidant, emulsification and flocculation activity. The EPS can be used as a natural additive for the pharmaceutical and food industries with potential applications in developing sustainable or ecofriendly additives.
A new study demonstrates how fluorescent cholesterol probes can visualize cholesterol in live cells, revealing its role in amyloid plaque formation and cellular signaling. The novel probes have the potential to enhance our understanding of how cholesterol imbalances contribute to neurodegenerative disorders.
Researchers have developed a method for delivering therapeutics to targeted locations in the human body using universal milk exosomes. This technology could be used to treat common and rare diseases alike, offering a potential boon to rare disease communities.
The study, published in the Journal of Clinical Oncology, showed no significant difference in patient survival between two-drug and three-drug chemotherapy regimens. The researchers found that the three-drug regimen may increase toxicity but could be a viable option for specific patients with certain types of biliary tract cancers.
A new study published in Aging found that pioglitazone reduced the frequency of skin ulcers in Werner syndrome patients. The research suggests that pioglitazone's anti-inflammatory properties may help wounds heal faster and prevent ulcers from forming.
A multidisciplinary team led by the Wyss Institute aims to create novel anesthesia-inducing drugs that can safely induce an anesthesia-like state without compromising vital functions. The project leverages expertise from Harvard's MCB, MIT, and Tufts University to develop safe battlefield-ready anesthetics.
Dr. Blagosklonny's work introduced a new theory and promoted the use of rapamycin to slow aging and extend healthy life by targeting the mTOR pathway, leading to improved immune responses, heart protection, and potential cancer prevention.
Mayo Clinic's Digital Pathology platform is transforming pathology by leveraging large datasets and AI models for faster, more accurate diagnoses. The partnership with NVIDIA and Aignostics aims to improve patient care and accelerate medical breakthroughs.
A recent case series suggests that an extended course of Paxlovid may help some patients with long Covid experience sustained improvements in their symptoms. The study, published in Communications Medicine, found that five out of 13 patients experienced significant symptom relief after taking the antiviral drug for 15 days.
Researchers will analyze tissue samples from 100 patients over three years to understand why some respond better than others to biologic and targeted therapies. The study aims to improve matching of treatments to individual patients, reducing the guesswork and cost associated with ineffective treatment.
Researchers have identified a new pathway for ergosterol biosynthesis in Leishmania parasites, paving the way for more effective antiparasitic drugs. The discovery reveals that azole antifungals targeting a specific enzyme can be highly effective against leishmaniasis.
Researchers provide comprehensive review of RSV's virology, clinical impact, and prevention strategies, emphasizing the need for effective vaccines to mitigate this critical health need. The review highlights RSV's severe impact on infants, children, and older adults, as well as its potential effects on multiple organs and systems.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
A study by UCSF researchers found that language, education, and age affect someone's ability to engage with digital health tools. Young English speakers are most comfortable using digital health tools, but others face barriers due to limited education or language proficiency.
A preclinical study suggests the experimental compound K884 can restore lost muscle function in Duchenne muscular dystrophy (DMD) patients by strengthening muscle repair. The drug targets specific enzymes, allowing muscle stem cells to develop into functional tissue.
A new blood test developed by RMIT University researchers could help personalize cancer treatments, making them safer and more effective. The test assesses how well different nanomedicines target cancer cells in the blood of leukemia patients, allowing for more tailored therapies.
The University of Surrey's research focuses on targeting mutated pathways with new drugs to treat rare conditions like immunodeficiencies. The team discovered that mTOR inhibitors can help restore normal B cell function.
Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...